Gray (Levofloxacin Hemihydrate)

Gray is indicated for community‑acquired pneumonia, acute bacterial sinusitis, uncomplicated urinary tract infections, acute exacerbations of chronic bronchitis, and skin or soft‑tissue infections.

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription, leading to bacterial cell death.

The safety of levofloxacin in pregnancy has not been established; it should be used only if the potential benefit justifies the potential risk to the fetus.

Common adverse effects include nausea, vomiting, diarrhea, headache, dizziness, and skin rash.

Serious reactions may include tendon rupture, peripheral neuropathy, severe allergic responses such as anaphylaxis or Stevens‑Johnson syndrome, QT prolongation, and Clostridioides difficile‑associated colitis.

Yes, patients with previous tendon disorders or those taking corticosteroids are at higher risk for tendon injury and should generally avoid fluoroquinolones like Gray.

Antacids containing aluminum, magnesium, or iron can reduce levofloxacin absorption and should be taken at least two hours apart from Gray.

Levofloxacin can increase the anticoagulant effect of warfarin, so more frequent monitoring of INR is recommended when the drugs are co‑administered.

Clinicians may monitor renal function, signs of tendon pain, QT interval on ECG, and for any signs of severe allergic reactions during therapy.

Levofloxacin is primarily excreted by the kidneys; dose adjustment may be required in patients with reduced renal function.

Levofloxacin is generally not recommended for routine use in children unless no alternative antibiotic is available and the benefits outweigh the risks.